Journal: International Journal of Molecular Sciences
Article Title: Anti-Algics in the Therapeutic Response of Breast and Urological Cancers
doi: 10.3390/ijms25010468
Figure Lengend Snippet: Effect of ( a ) Lid, ( b ) Rop, and ( c ) Lev on metabolic activity of human breast cancer (MCF7), prostate cancer (LNCaP and PC3), bladder cancer (TCCSUP and HT1376), and non-malignant (MCF12A, HaCaT, and RWPE-1) cell lines. Metabolic activity was evaluated as a measure of cell proliferation, by colorimetric MTT assay, 48 h after treatment with Lid (0.3–10 mM), Rop (0.01–1 mM), or Lev (0.01–1 mM). In cases where sigmoid fitting adjustment was possible, dose–response curves were obtained (R 2 > 0.91) and the half maximal inhibitory concentrations (IC 50 ) were calculated. The values are given as the mean ± SEM of, at least, three independent experiments in triplicate.
Article Snippet: Human cancer cell lines of prostate (LNCaP, ATCC ® CRL-1740TM and PC3, ATCC ® CRL-1435TM), breast (MCF-7, ATCC ® HTB-22TM), bladder (TCCSUP, ATCC ® HTB-5TM and HT1376, ATCC ® CRL-1472TM), as well as human normal prostate (RWPE-1, ATCC ® CRL-11609TM), breast (MCF12A, ATCC ® CRL-10782TM), and keratinocytes (HaCaT, ATCC ® PCS-200-011TM) cell lines were used to conduct the experiments.
Techniques: Activity Assay, MTT Assay